Full Text View
Tabular View
No Study Results Posted
Related Studies
A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
This study is currently recruiting participants.
Study NCT00217295   Information provided by Multiple Sclerosis Institute
First Received: September 14, 2005   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Multiple Sclerosis
Additional conditions recognized in this trial
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Interventions listed in this trial
Avonex and Topamax
Additional drug interventions recognized in this trial
Interferon beta 1a
Topiramate
More general drug interventions related to this trial
Adjuvants, Immunologic
Anti-Obesity Agents
Anticonvulsants
Antineoplastic Agents
Central Nervous System Agents
Immunologic Factors
Neuroprotective Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Multiple Sclerosis Institute


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services